TherapeuticsMD (TXMD) Misses Q1 EPS by $1.69
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
TherapeuticsMD Announces First Quarter 2022 Financial Results
May 16, 2022 4:05 PM EDT
- Quarterly total net product revenue of $19.3 million -
- ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 -
- Announced and completed vitaCare divestiture in five weeks -
- Conference call scheduled for 4:30 p.m. ET today -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (TXMD or the Company) (NASDAQ: TXMD), an innovative, leading womens healthcare company, today reported financial results for the first quarter ended March 31, 2022.
Our revenue performance during the quarter was impacted by ANNOVERA manufacturing challenges as anticipated, but we believe these... More
